mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
PEAKS and NovoHMM had the best sensitivity in both QSTAR and LCQ data as well. However, no evaluated algorithms exceeded a 50% of exact identification for both data sets. Recent progress in mass spectrometers made it possible to generate mass spectra of ultra-high resolution [1]. The improved accuracy, together with the increased amount of mass spectrometry data that are being generated, draws the interests of applying deep learning techniques to de novo peptide sequencing. In 2017 Tran et al. proposed DeepNovo, the first deep learning based de novo sequencing software. The benchmark analysis in the original publication demonstrated that DeepNovo outperformed previous methods, including PEAKS, Novor and PepNovo, by a significant margin. DeepNovo is implemented in python with the Tensorflow framework. To represent a mass spectrum as a fixed-dimensional input to the neural-network, DeepNovo discretized each spectrum into a length 150,000 vector. This unnecessarily large spectrum representation, and the single-thread CPU usage in the original implementation, prevents DeepNovo from performing peptide sequencing in real time. To further improve efficiency of de novo peptide sequencing models, Qiao et al. proposed PointNovo in 2020. PointNovo is a python software implemented with the PyTorch framework and it gets rid of the space consuming spectrum-vector-representation adopted by DeepNovo. Comparing with DeepNovo, PointNovo managed to achieve better accuracy and efficiency at the same time by directly representing a spectrum as a set of m/z and intensity pairs.
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new antihistamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation" and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better-stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg in surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterward. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders.
=== Metabolic activity === Several studies have investigated didymin's potential in metabolic disorders. In high-fat diet mouse models, didymin reduced postprandial blood glucose levels and improved insulin secretion by enhancing mitochondrial biogenesis and function in pancreatic beta cells. In a separate study, didymin alleviated metabolic dysfunction-associated fatty liver disease (MAFLD) in mice by activating Sirt1, thereby stimulating lipophagy and mitochondrial biogenesis. In insulin-resistant HepG2 cells, didymin enhanced glucose uptake and activated insulin receptor substrate-1, PI3K, Akt, and glycogen synthase kinase-3 (GSK-3), while inhibiting key enzymes of gluconeogenesis.
Sources: en.wikipedia.org
He wrote that: "They want to control our brotherhood... It is up to authentic Cuban Freemasons to prevent any of this from happening; once aware of the ever-growing influence State Security seeks to exert over our institution, we must not allow anyone likely linked to these agencies to assume the position." After arriving in the United States, Alfonso Vidal told reporters that former Grand Master Zamora Fernández, despite publicly appearing to stand against the injustice of the Cuban government, had privately apologized to the Communist Party. Alfonso Vidal said that at a special session of the Cuban Supreme Court of Masonic Justice, Zamora Fernández accused Master Mason Brian José Infante Machín from Logia Luz Caballero (English: Luz Caballero Lodge) of leading a conspiracy against the government, after which the Supreme Court expelled Infante Machín. Alfonso Vidal said that: "Zamora Fernández is weak-willed; his desire for recognition makes him vulnerable to State Security. I caught him crying the day he had to leave his post, and even now he hasn't come to terms with the fact that he's no longer the Grand Master. State Security takes advantage of all this; they seem to study your profile. They repeatedly emphasized that I was a noble and humble person, and that's how they approached me. Furthermore, officials from the Office of Religious Affairs speak very highly of him; in fact, they were confident that I would follow in Zamora's footsteps." He also called on the Freemasons of Cuba to elect Viñas Alonso as the Grand Master of Cuba.
=== Saudi Arabia === In Saudi Arabia, an MD must pass the Saudi Medical License Exam (SMLE) to apply for medical residency programs. The competitiveness of residency programs varies by specialty and region, with Plastic Surgery, Ophthalmology, Dermatology, and ENT being the most competitive. Residency durations range from 3 to 7 years, depending on the specialty. All residency programs include an end-of-training medical exam, which is conducted in English, as a requirement for board certification.
=== Halogenation === Direct difluoromethylation via Zn(SO2CF2H)2 N–X Anomeric Amides as Electrophilic Halogenation Reagents (2023) Guanidine-based chlorinating reagent, CBMG or "Palau'chlor" (2014) Regioselective bromination of N-oxides (2013)
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.